Ketamine improves ovarian function and egg quality in stress-induced depressed mice via ferroptosis

A new study in mice suggests that ketamine may do more than rapidly relieve depressive-like symptoms: it may also protect ovarian function and improve the quality of eggs affected by chronic stress. Published in Cell Death Discovery, the research by Liu, Jiang, Wang and colleagues links the reproductive benefits of ketamine to ferroptosis, a form of regulated cell death driven by iron-dependent lipid damage. The findings add a surprising dimension to research on depression, showing how prolonged psychological stress may influence reproductive biology at the cellular level.

The researchers used a mouse model in which depression-like changes were induced with corticosterone, often abbreviated as CORT. Corticosterone is the primary stress hormone in rodents and is functionally comparable to cortisol in humans. When exposure remains high for an extended period, it can disrupt the brain’s stress-response system and affect organs beyond the nervous system. In the ovary, chronic stress may interfere with hormone signaling, follicle development, mitochondrial activity and the environment surrounding growing oocytes.

Ovarian function depends on the coordinated maturation of follicles, the hormone-producing structures that contain developing oocytes. Healthy follicles require tightly regulated communication among oocytes, granulosa cells and the surrounding ovarian tissue. Stress-related hormonal imbalance can disturb this system, potentially reducing the number of functional follicles and compromising the conditions needed for oocyte maturation. Because oocyte quality is closely linked to early embryonic development, damage occurring before fertilization may have consequences that extend beyond the ovary itself.

The study focuses on ferroptosis as a possible mechanism behind this damage. Unlike apoptosis, the best-known form of programmed cell death, ferroptosis is characterized by the accumulation of iron and the uncontrolled oxidation of polyunsaturated fatty acids in cell membranes. As lipid peroxides build up, membranes lose their integrity and cells become vulnerable to destruction. The process is normally restrained by antioxidant systems, including glutathione-dependent pathways and enzymes that neutralize lipid peroxides. When these defenses fail, iron-catalyzed oxidative reactions can accelerate cellular injury.

In the CORT-treated mice, the investigators reported impaired ovarian performance and poorer oocyte quality alongside changes consistent with ferroptotic stress. The work indicates that chronic exposure to a stress-hormone environment may increase oxidative pressure in reproductive tissues, weakening the antioxidant balance that protects ovarian cells. Such a mechanism is biologically plausible because ovaries contain active mitochondria, rapidly changing membranes and metabolically demanding cells, all of which can become sensitive to excessive reactive oxygen species.

Ketamine was then examined as an intervention. Best known as an anesthetic and dissociative drug, ketamine has also emerged as a rapid-acting antidepressant, particularly because it can reduce depressive symptoms through mechanisms that differ from conventional serotonin-based treatments. Its primary pharmacological action involves blocking N-methyl-D-aspartate, or NMDA, receptors, a class of glutamate receptors involved in learning, synaptic plasticity and neural stress responses. The drug’s effects, however, may extend through downstream pathways that influence inflammation, metabolism, oxidative balance and cellular survival.

According to the study, ketamine treatment improved measures of ovarian function and oocyte quality in the CORT-induced depression model. The researchers linked this improvement to suppression of ferroptosis-related damage, suggesting that ketamine may help restore the balance between oxidative injury and antioxidant protection. Rather than viewing the drug solely as a psychiatric treatment, the findings raise the possibility that its biological effects can influence multiple systems affected by chronic stress. The research also supports the idea that protecting cells from lipid peroxidation could become a strategy for preserving reproductive health under adverse physiological conditions.

The proposed connection between ketamine and ferroptosis remains especially important because it provides a mechanistic bridge between mental health and fertility research. Depression and prolonged stress are associated with changes in endocrine signaling, sleep, immune activity and metabolism, all of which can affect reproductive function. If ferroptotic injury contributes to ovarian dysfunction, then future therapies might target iron handling, lipid oxidation or antioxidant pathways directly. Such approaches could eventually complement psychological treatment, although the present findings do not establish that ferroptosis is the only pathway involved.

The results should be interpreted within the limits of an animal study. A CORT-induced mouse model reproduces selected biological and behavioral features of depression, but it cannot capture the full complexity of human depression, which arises from diverse genetic, environmental and medical factors. Mouse ovarian physiology also differs from human reproductive biology, and an intervention that improves oocyte-related outcomes in mice may not produce the same effects in people. Ketamine carries important risks, including dissociative effects, blood-pressure changes and the potential for misuse, so these findings do not justify using it to enhance fertility outside carefully controlled medical research.

Even with those limitations, the study offers a notable shift in perspective. It suggests that the reproductive consequences of chronic stress may be partly driven by a form of oxidative cell death that can be modified pharmacologically. The work could encourage further experiments examining whether ketamine’s ovarian effects depend on its antidepressant action, on direct protection of reproductive cells, or on both. Researchers will also need to determine how long the benefits last, whether they improve fertilization and embryo development, and whether safer compounds can reproduce the same ferroptosis-related protection. For now, the study provides an intriguing molecular explanation for how a drug acting in the brain might also influence the biology of the ovary.